JanOne Inc. (JAN)
| Market Cap | 16.75M |
| Revenue (ttm) | 33.87M |
| Net Income (ttm) | -8.50M |
| Shares Out | 1.85M |
| EPS (ttm) | -3.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $6.97 |
| Previous Close | $7.70 |
| Change ($) | -0.73 |
| Change (%) | -9.48% |
| Day's Open | 7.52 |
| Day's Range | 6.87 - 7.67 |
| Day's Volume | 241,949 |
| 52-Week Range | 2.26 - 31.83 |
LAS VEGAS, Feb. 2, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving propertie...
LAS VEGAS, Jan. 29, 2021 /PRNewswire/ -- JanOne Inc. (NASDAQ: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properti...
JanOne (NASDAQ: JAN) shares are trading higher as speculative retail trading, particularly among the Reddit community, continues to drive volatility in the stock. JanOne is focused on reducing opioid ad...
JanOne (JAN) stock is soaring higher Thursday morning as it joins other stocks being boosted by Reddit and other social media users. The post JAN Stock: JanOne Shares Skyrocket as Part of Reddit Run-Up ...
LAS VEGAS, Sept. 22, 2020 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving propert...
LAS VEGAS, Sept. 16, 2020 /PRNewswire/ -- JanOne Inc.
LAS VEGAS, Aug. 28, 2020 /PRNewswire/ -- JanOne Inc.
LAS VEGAS, Aug. 26, 2020 /PRNewswire/ -- JanOne Inc.
JanOne Inc. (JAN) CEO Tony Isaac on Drug Candidate JAN101 - Telebriefing and Corporate Update Call Transcript
LAS VEGAS, Aug. 21, 2020 /PRNewswire/ -- JanOne Inc.
LAS VEGAS, Aug. 19, 2020 /PRNewswire/ -- JanOne Inc.
LAS VEGAS, Aug. 11, 2020 /PRNewswire/ -- JanOne Inc.
LAS VEGAS, Aug. 6, 2020 /PRNewswire/ -- JanOne Inc.
LAS VEGAS, Aug. 4, 2020 /PRNewswire/ -- JanOne Inc.
LAS VEGAS, July 30, 2020 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a company focused on finding treatments for conditions that cause severe pain and bringing to market drugs and therapies with non-addic...
LAS VEGAS, July 8, 2020 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a company focused on finding treatments for conditions that cause severe pain and bringing to market drugs and therapies with non-addict...
LAS VEGAS, June 30, 2020 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a company focused on finding treatments for conditions that cause severe pain and bringing to market drugs and therapies with non-addic...
LAS VEGAS, June 25, 2020 /PRNewswire/ -- JanOne Inc. (NASDAQ: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive pain relieving p...
About JAN
JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain. It operates in three segments: Biotechnology, Recycling, and Technology. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral art... [Read more...]
| Industry Waste Management | Founded 1976 |
| Stock Exchange NASDAQ | Ticker Symbol JAN |
Financial Performance
In 2020, JanOne's revenue was $33.87 million, a decrease of -3.50% compared to the previous year's $35.10 million. Losses were -$8.50 million, -28.97% less than in 2019.
Analyst Forecasts
The average 12-month stock price forecast for JanOne is 4.00, which is a decrease of -42.61% from the latest price.